Chronic Kidney Disease in Children (CKiD V)

项目总结/摘要 对于儿童慢性肾脏病（CKiD）研究更新，我们将继续随访现有队列， 并将招募14至17岁的儿童，以加强研究的力量， 肾功能下降和心血管疾病的发展，因为他们过渡到年轻的成年。 将通过国家实验室承包商协调和进行远程数据收集，这些承包商可以 评估生命体征并在参与者家中进行实验室检查。将通过以下方式在CKiD研究访视之间获取数据： 通过电子健康记录进行数据提取。研究电子数据采集（REDCap） 将利用系统自动报告协调和临床活动，并改进选项 与外部队列（包括CureGN和NEPTUNE）协调。最重要的是，它将使 研究通过计算机或移动的电话直接由参与者通过基于网络的输入收集数据。 重要的研究问题将包括（a）确定肾功能下降的风险因素的方法， 儿童期至青年期，包括肾小球滤过率（GFR）下降加速， 青春期和急性肾损伤（阿基）对慢性肾病（CKD）的影响;（B）基于药物的机器 学习预测方法，以表征临床标志物和社会指标的联合预测值。 用于个体化推断的疾病进展决定因素;（c）描述风险因素的分析策略 通过家庭血压监测和评估心血管变化和结局， 血管靶器官损伤，包括表征生物标志物的变化，如血管靶器官损伤指标的轨迹， 代谢性骨健康;（d）验证和完善青年GFR方程的统计方法， 在从儿科护理向成人护理过渡期间的一致估计数;以及（e）评估 治疗和暴露的结果，包括社会功能和情绪健康的结构。

PROJECT SUMMARY/ABSTRACT For the Chronic Kidney Disease in Children (CKiD) Study renewal, we will continue to follow our existing cohort, and will recruit children between 14 and 17 years of age to enhance the power of the study to characterize the decline of kidney function and the development of cardiovascular disease as they transition to young adulthood. Remote data collection will be coordinated and conducted through national laboratory contractors who can assess vitals and obtain labs in the participant’s home. Data will be obtained between CKiD study visits by conducting data extraction through electronic health records. The Research Electronic Data Capture (REDCap) system will be leveraged to allow automated reporting for coordination and clinical activities and improve options for harmonization with external cohorts including CureGN and NEPTUNE. Most importantly, it will enable the study to collect data through web-based entry by computer or mobile phone directly by participants. Important research questions will include (a) methods to identify risk factors for decline in kidney function during childhood through young adulthood including acceleration of glomerular filtration rate (GFR) decline during puberty and the effect of acute kidney injury (AKI) on chronic kidney disease (CKD); (b) statistical-based machine learning prediction methodology to characterize the joint predictive value of clinical markers and social determinants of disease progression for individualized inference; (c) analytic strategies to describe risk factors for cardiovascular changes and outcomes via home blood pressure monitoring and assessing cardiac and vascular target organ damage, including characterizing changes in biomarkers like trajectories of indicators of metabolic bone health; (d) statistical methods to validate and refine GFR equations in young adulthood for consistent estimates during the transition from pediatric to adult care; and (e) methods to assess effects of therapies and exposures on outcomes including constructs of social function and emotional well-being.